Introduction
============

Mithramycin **1** ([Fig. 1](#f1){ref-type="fig"}) is an antitumour compound of the aureolic acid family produced by *Streptomyces argillaceus* ([@b33]), which was discovered in 1961 and approved for use as anticancer drug in 1970 ([@b27]). It has been used clinically for the treatment of several types of cancer, including testicular carcinoma, chronic myeloid leukaemia and acute myeloid leukaemia and also for the control of hypercalcaemia in patients with malignant diseases ([@b31]; [@b40]). More recently, renewed interest for **1** is growing because of its potential new applications. It has been found that **1** could be used in combination with bevacizumab, a neutralizing antibody against VEGF (Vascular Endothelial Growth Factor), as a novel antiangiogenic therapy for pancreatic cancer and other cancers ([@b15]). Moreover, **1** has revealed to be a neuroprotective drug, possessing potential application as neurological therapeutics, and for the alleviation of symptoms underlying β‐thalassaemia and sickle cell anaemia due to its activity as inducer of erythrocitic cell differentiation ([@b9]; [@b13]). The antitumour properties of **1** are due to its inhibitory effects on replication and transcription processes during macromolecular biosynthesis by interacting, in the presence of Mg^2+^, with GC‐rich nucleotide sequences located in the minor groove of DNA ([@b35]; [@b36]; [@b4]). As a consequence it blocks the binding of proteins to GC‐rich sequences in gene promoters, and inhibits transcription of genes regulated by these factors, such as those regulated by the Sp1 family of transcription factors ([@b23]; [@b30]; [@b5]; [@b41]).

![Chemical structures of compounds used as substrates in this work: mithramycin **1**, Chromomycin A~3~**2**, 4A,4E‐*O*‐dideacetyl‐chromomycin A~3~**3**, demycarosyl‐mithramycin **4**, demycarosyl‐3D‐β‐[d]{.smallcaps}‐digitoxosyl‐mithramycin **5**, dideolivosyl‐6‐β‐[d]{.smallcaps}‐amicetosyl‐mithramycin **6**, deoliosyl‐demycarosyl‐3C‐β‐[d]{.smallcaps}‐boivinosyl‐mithramycin **7**, dideolivosyl‐6‐β‐[d]{.smallcaps}‐amicetosyl‐deoliosyl‐3C‐β‐[d]{.smallcaps}‐olivosyl‐mithramycin **8**, mithramycin SK **9** and mithramycin SDK **10**.](mbt0004-0226-f1){#f1}

Chromomycin A~3~**2** ([Fig. 1](#f1){ref-type="fig"}) is an antitumour compound structurally related to **1**, but differing in the glycosylation pattern. Mithramycin contains a trisaccharide of [d]{.smallcaps}‐olivose, [d]{.smallcaps}‐oliose and [d]{.smallcaps}‐mycarose, and a disaccharide of [d]{.smallcaps}‐olivose, while **2** contains a trisaccharide of [d]{.smallcaps}‐olivose, [d]{.smallcaps}‐olivose and 4‐*O*‐acetyl‐[l]{.smallcaps}‐chromose B, and a disaccharide of 4‐*O*‐acetyl‐[d]{.smallcaps}‐oliose and 4‐*O*‐methyl‐[d]{.smallcaps}‐oliose attached at positions 2 and 6 of the aglycone respectively. These differences in the stereochemistry and functional group substitutions of the sugars are expressed in the binding properties of these compounds to DNA ([@b18]; [@b24]). Thus, the acetoxy groups in [d]{.smallcaps}‐oliose (sugar A) and [l]{.smallcaps}‐chromose B (sugar E) in **2** provide additional H‐bonds with the 2‐amino groups of G‐bases and thus adding more specificity to the DNA binding ([@b38]; [@b39]; [@b18]; [@b8]). This is also shown in their antitumour activities, where **2** is approximately 10 times more active than **1** against several tumour cell lines ([@b19]; [@b29]). We have cloned and characterized the gene cluster involved in the biosynthesis of **2** ([@b19; @b20; @b21; @b22]). It contains the *cmmA* gene, which encodes the acetyltransferase responsible for transferring both acetyl groups to [d]{.smallcaps}‐oliose and [l]{.smallcaps}‐chromose B during **2** biosynthesis ([@b20]). Inactivation of *cmmA* leads to the accumulation of 4A,4E‐*O*‐dideacetyl‐chromomycin A~3~ (**3**) ([Fig. 1](#f1){ref-type="fig"}), which differs from the parental compound by lacking the two acetyl groups, and being approximately 100 times less active, which confirms the importance of the acetyl groups for the antitumour activity of **2** ([@b20]).

In this article we report the use of CmmA to increase the structural diversity of mithramycins and to generate novel mithramycins with antitumour activity. We also show that CmmA is located in the cell membrane and exhibits substrate flexibility using different acyl‐CoAs as donor substrates.

Results and discussion
======================

Generation of acetylated analogues of mithramycin by bioconversion
------------------------------------------------------------------

Two sugars ([l]{.smallcaps}‐chromose B and one [d]{.smallcaps}‐oliose) in **2** are acetylated at the C4 hydroxyl groups ([Fig. 1](#f1){ref-type="fig"}). These acetyl groups are incorporated into the molecule by the chromomycin acetyltransferase CmmA ([@b20]). Since these groups greatly increase the antitumour activity of **2**, we decided to use CmmA in order to generate acetylated derivatives of **1** with high antitumour activity. To achieve this, we performed a bioconversion experiment by growing the wild‐type strain *Streptomyces griseus* ssp. *griseus* (chromomycin A~3~ producer) that was subsequently fed with **1**. These cultures were then extracted and analysed by HPLC‐MS. In addition to **1**, a new peak was detected showing the same absorption spectrum than **1**, but with higher retention time and an m/z value in positive mode of 1128 (data not shown). This is in agreement with compound **1** with one acetyl group attached. We also tested if this acetylation event was CmmA‐dependent by running a bioconversion experiment using *S. griseus* C10A as host (*cmmA*^‐^ mutant). No acetylated mithramycin was obtained in these conditions confirming that CmmA is required for this acetylation process (data not shown). This result showed that CmmA was flexible enough to be able to acetylate **1**. The bioconversion efficiency using the wild‐type strain was rather low (approximately 14%). Most probably this was due to the fact that the acetyltransferase CmmA has more affinity to its genuine substrate and/or was mainly committed to the biosynthesis of **2**. With the aim of improving the production of acetylated derivatives of **1**, we tested the bioconversion efficiencies as biocatalysts of different mutant strains of *S. griseus* affected in biosynthesis of **2**. These mutants (C60GI, C10GII, G10GIII and G10GIV; [Fig. 2](#f2){ref-type="fig"}) expressed the acetyltransferase CmmA but were blocked in glycosylation steps taking place before the acetylation of sugars, and therefore preventing the synthesis of potential natural substrates for CmmA. When any of these mutants was used in bioconversion experiments with **1** as substrate, higher production of monoacetylated mithramycin **11** was obtained. Since *S. griseus* C10GIV was more efficient than the other mutant strains in the bioconversion experiments (35% of conversion, [Fig. 3A](#f3){ref-type="fig"}), it was selected as biocatalyst for further experiments.

![Scheme showing the glycosylation steps blocked during chromomycin biosynthesis in mutants *S. griseus* C60GI, C10GII, C10GIII and C10GIV.](mbt0004-0226-f2){#f2}

![HPLC analyses of cultures of *S. griseus* C10GIV fed with: (A) mithramycin **1**; (B) demycarosyl‐mithramycin **4**; (C) demycarosyl‐3D‐β‐[d]{.smallcaps}‐digitoxosyl‐mithramycin **5**; (D) dideolivosyl‐6‐β‐[d]{.smallcaps}‐amicetosyl‐mithramycin **6**; (E) deoliosyl‐demycarosyl‐3C‐β‐[d]{.smallcaps}‐boivinosyl‐mithramycin **7**; (F) dideolivosyl‐6‐β‐[d]{.smallcaps}‐amicetosyl‐deoliosyl‐3C‐β‐[d]{.smallcaps}‐olivosyl‐mithramycin **8**; (G) mithramycin SK **9**; and (H) mithramycin SDK **10**. Acetylated derivatives with one (★), two (![](mbt0004-0226-fu1.jpg)) or three (▴) acetyl groups. Compounds **11** to **17** are bioconversion products and were purified and characterized (see [Fig. 4](#f4){ref-type="fig"} for chemical structures).](mbt0004-0226-f3){#f3}

Our next goal was to generate acetylated derivatives of different analogues of **1**, which differ from **1** either in the glycosylation pattern ([Fig. 1](#f1){ref-type="fig"}, compounds **4** to **8**) or in the structure of the aglycone side‐chain ([Fig. 1](#f1){ref-type="fig"}, compounds **9** and **10**). *Streptomyces griseus* C10GIV was fed with all these compounds independently and the cultures were analysed by HPLC and HPLC‐MS ([Fig. 3B--H](#f3){ref-type="fig"}). In all the cases new peaks were detected which corresponded to monoacetylated derivatives, as deduced from the higher retention times and masses of the novel compounds, differing in 42 units in comparison with the respective substrates. These mass changes are consistent with the incorporation of a single acetyl group to the compound. Bioconversions with some compounds led to the formation of several derivatives with the same mass (monoacetylated), but with different retention times (compounds **4**, **5** and **6** shown in [Fig. 3B, C and D](#f3){ref-type="fig"}), suggesting that acetylations took place in different positions of the substrates. Moreover, bioconversions with compounds **4**, **5**, **7** and **9**, and also **1** resulted in the generation of compounds with mass differing in 84 units from the corresponding substrates, being consistent with the generation of derivatives with two acetyl groups attached ([Fig. 3A, C, E and G](#f3){ref-type="fig"}). Also, an analogue of compound **5** was obtained with an m/z value in positive mode of 1197 (peak **16** in [Fig. 3C](#f3){ref-type="fig"}), which is consistent with the incorporation of three acetyl groups to compound **5**.

Isolation and structure elucidation of selected compounds
---------------------------------------------------------

Some acetylated compounds were selected for purification and further characterization. Selection was mainly based on the antitumour activity of the parental compounds, but also considering the yields and the possible structural diversity of the acetylated derivatives. In total we purified seven compounds: one derivative from **1** (compound **11**, [Fig. 3A](#f3){ref-type="fig"}), five from **5** (compounds **12** to **16**, [Fig. 3C](#f3){ref-type="fig"}) and one from **9** (compound **17**, [Fig. 3G](#f3){ref-type="fig"}). These compounds were purified by preparative HPLC from cultures of *S. griseus* C10GIV fed with the corresponding substrates. The acetylated compounds were initially identified by HPLC‐MS analyses by comparing the UV absortion spectrum and analysing the mass of the molecular ion. For the new derivative obtained from **1** (compound **11**) a molecular formula of C~54~H~78~O~25~ (m/z: 1128) was deduced, indicating the incorporation of one acetyl group into the trisaccharide moiety. Similarly, mass spectra of the five derivatives isolated from **5** revealed three monoacetylated derivatives (compounds **12** to **14**) with a molecular formula of C~53~H~76~O~25~ (m/z: 1114), one diacetylated derivative (compound **15**) with a molecular formula of C~56~H~80~O~25~ (m/z: 1156) and one triacetylated derivative (compound **16**) with a molecular formula of C~58~H~82~O~26~ (m/z: 1198), all of them acetylated in the trisaccharide chain. The compound **17** isolated from **9** showed a molecular formula of C~53~H~76~O~24~ (m/z: 1098), indicating the presence of one acetyl group in the trisaccharide chain again. Final identification of the novel compounds was carried out by ^1^H mono‐ and bidimensional NMR experiments (COSY, TOCSY) (see *Supporting information*). The acetylated positions in the novel analogues were identified by comparing the corresponding spectra with those previously described for compounds **1**, **5** and **9** ([@b42]; [@b32]; [@b3]). The chemical structures of the isolated compounds are shown in [Fig. 4](#f4){ref-type="fig"}.

![Chemical structures of new acetylated derivatives of (A) mithramycin **1**, (B) demycarosyl‐3D‐β‐[d]{.smallcaps}‐digitoxosyl‐mithramycin **5** and (C) mithramycin SK (**9**). Acetyl groups are highlighted with circles.](mbt0004-0226-f4){#f4}

These new compounds differ from the parental compounds in the presence of one, two or three acetyl groups attached at specific positions of different sugars of the saccharide chains. Three different hydroxyl groups in mithramycins were susceptible of being acetylated by CmmA, those located at C3 and C4 of sugar E and the one at position C4 of sugar D. Acetylation at 3E occurred when [d]{.smallcaps}‐digitoxose was the distal sugar of the trisaccharide chain instead of [d]{.smallcaps}‐mycarose, as it happens in **5;** it is likely that the presence of the C‐methyl group at C3 in [d]{.smallcaps}‐mycarose prevents the access of CmmA to that position. In chromomycins, the 4E hydroxyl group is the most common acetylated position. On the contrary, no chromomycin has been identified yet with an acetyl group at 3E ([@b20; @b21]). Most probably, the existence of a C‐methyl group at C3 in [l]{.smallcaps}‐chromose B (sugar E) in **2** would prevent the acetylation event. On the other hand, 4D position is susceptible to acetylation in mithramycins but not in chromomycins. This could be explained because sugar D in mithramycins is a [d]{.smallcaps}‐oliose while in chromomycins is a [d]{.smallcaps}‐olivose. These two sugars only differ in the configuration of the hydroxyl group at C4, axial in the former and equatorial in the latter, which highlights the importance of the configuration of that hydroxyl group to be acetylated. On the contrary, no compound was produced with acetyl groups in the disaccharide chain of **1** or its derivatives. This is in contrast to what happens in **2** where the 4A position is normally acetylated, and the 3A and 4B positions are occasionally acetylated ([@b20]). These differences could be also explained by the different sugar configuration of the disaccharide chain in both compounds, consisting of [d]{.smallcaps}‐olivoses in **1** and in some analogues, and [d]{.smallcaps}‐olioses in **2**. In summary, based on the structures of known chromomycins and acetylated mithramycin compounds reported in this article, it seems that CmmA has preference for hydroxyl groups in axial configuration and not for those in equatorial configurations, unless these are located at the third sugar of the trisaccharide chain; approximately 59% of acetylated mithramycin compounds obtained by bioconversion are acetylated at hydroxyl groups in axial configuration, versus 39% in equatorial configuration.

The generation of different types of acetylated mithramycins indicates that CmmA shows substrate acceptor flexibility, both regarding the position and type of sugar acetylated and also regarding the structure of the side‐chain of the aglycone. In this respect, we were able to generate acetylated derivatives of mithramycins independently of the structure and length of their side‐chain.

Antitumour activity
-------------------

The antitumour activity of the new mithramycin analogues was tested against four tumour cell lines ([Table 1](#t1){ref-type="table"}). Compilation of the average GI~50~ (50% of growth inhibition) values showed that all of the compounds were active at micromolar concentrations and most of them were also active at 0.1 µM or lower. In general, all compounds were less active against glioblastoma cancer cells. This was particularly noticeable for compounds **12** and **15**. This different behaviour could be ascribed to differences in gene expression patterns that are specific to each cell line ([@b11]). Compound **12** showed improved activity against colon cancer cells (about five times higher activity than the parent compound **5**). Moreover, compound **14** was particularly active against glioblastoma cancer cells in relation to its parent compound (activity up to five times higher than that of compound **5** from which it derives), and compounds **12**, **13** and **16** were better against pancreas tumour cells (about five times more active than the parent compound **5)**. This could be particularly important since glioblastoma is one of the most common tumours of the central nervous system, and despite many efforts to overcome this aggressive disease the median survival for patients with glioblastoma is only 1 year ([@b37]). On the other hand, the treatment of pancreatic cancer remains elusive; in spite of treatment, \< 5% of patients remain alive after 5 years ([@b10]). Therefore, development of new compounds with high activity against pancreatic tumours is currently most demanding Interestingly, most of those mithramycins with improved activities bear one acetyl group (e.g. compounds **12**, **13**, **14)**, but there were other compounds with two or three acetyl groups (e.g. compound **16**). This indicates that apparently there is no correlation between the number of acetyl groups and the antitumour activity.

###### 

Antitumour activity of compounds.

  Tumour cell lines   GI~50~ (µM)                                                           
  ------------------- ------------- ------ ------ ------ ------ ------ ------ ------ ------ ------
  Glioblastoma T98G   0.35          0.22   0.36   1.81   0.34   0.07   1.59   0.31   0.35   0.52
  NSCL A549           0.03          0.05   0.06   0.03   0.04   0.03   0.03   0.03   0.02   0.05
  Colon H116          0.02          0.01   0.05   0.01   0.03   0.03   0.03   0.02   0.02   0.01
  Pancreas PSN1       0.02          0.05   0.05   0.01   0.01   0.02   0.02   0.01   0.02   0.05

GI~50~, 50% growth inhibition; NSCL, non‐small cell lung.

Localization and *in vitro* assay of CmmA
-----------------------------------------

In order to *in vitro* assay CmmA, its coding gene was subcloned in pEM4T under the control of the erythromycin resistance promoter (*ermE*\**p*) and expressed in *Streptomyces albus*. Correct expression of *cmmA* in this strain (*S. albus* pEM4TCmmA) was verified by carrying out a bioconversion experiment using as substrate 4A,4E‐*O*‐dideacetylchromomycin A~3~**3**, its natural substrate. This was readily converted into **2**, while a *S. albus* strain containing an empty vector was unable to carry out that bioconversion (data not shown). Next, localization of CmmA in the hyphae was attempted. Mycelia from *S. albus* pEM4TCmmA and *S. albus* pEM4T (as control) were fractionated into soluble and membrane fractions and the fractions were analysed by Western blotting using anti‐CmmA serum. No positive signals were shown in fractions from *S. albus* pEM4T ([Fig. 5A](#f5){ref-type="fig"}). However, positive signals were detected in the membrane fractions but not in the soluble fraction of *S. albus* pEM4TCmmA ([Fig. 5A](#f5){ref-type="fig"}), which is consistent with the location of CmmA in the cell membrane. These fractions were also tested for acetyltransferase activity using an *in vitro* assay. Again, fractions from the control strain did not shown acetyltransferase activity (data not shown). However, cell‐free extracts and membrane but not soluble fractions from *S. albus* pEM4TCmmA were able to acetylate **3** generating **2**, in the presence of acetyl‐CoA ([Fig. 5B](#f5){ref-type="fig"}). In this reaction two other compounds were also produced that could correspond to monoacetylated derivatives of **3**, since their masses were consistent with the incorporation of a single acetyl group to **3**. These results clearly demonstrate that CmmA is located and active in the cell membrane. This location is consistent with the idea that in the biosynthesis pathway of chromomycin A~3~ acetylation of sugars is one of the latest biosynthesis steps, taking place in close relation to its secretion.

![Localization and *in vitro* assay of CmmA. A. Western analysis of cell‐free extracts (CE), soluble fraction (SF) and membrane fraction (MF) using anti‐CmmA serum. a, control *S. albus* (pEM4T); b, *S. albus* (pEM4TcmmA). B. Analysis by HPLC of products from *in vitro* assays using acetyl‐CoA and 4A,4E‐*O*‐dideacetyl‐chromomycin A~3~ as substrates and cell‐free extract, soluble fraction and membrane fraction of *S. albus* (pEM4TcmmA) as a source of CmmA. **2**, chromomycin A~3~; **3**, 4A,4E‐*O*‐dideacetyl‐chromomycin A~3~; (★) monoacetylated derivatives of **3**.](mbt0004-0226-f5){#f5}

We also tested the possibility of CmmA to use different donor substrates. We screened short straight‐ and branched‐chain acyl‐CoAs (C~3~ and C~4~). Of all acyl‐CoA donors tested only C~3~ chain acyl‐CoAs (isobutyryl‐ and propionyl‐CoA) were utilized by CmmA, whereas longer‐chain‐length acyl‐CoAs (isovaleryl‐, isobutyryl‐CoA and β‐methylcrotonyl‐CoA) were not. When isobutyryl‐CoA was used, a new peak with a higher retention time and an m/z value in positive mode of 1169 was produced ([Fig. 6A](#f6){ref-type="fig"}), which is consistent with the incorporation of an isobutyryl group to **3**. When the donor substrate was propionyl‐CoA, two new compounds were produced that showed higher retention times than **3** ([Fig. 6B](#f6){ref-type="fig"}), and with m/z values in positive mode of 1155 and 1211. These masses were consistent with the incorporation of one and two propionyl groups to **3** respectively. Propionyl‐ and Isobutiryl‐CoA were not used with the same efficiency by CmmA, being the former better substrate than the latter. As shown in [Fig. 6](#f6){ref-type="fig"}, the use of propionyl‐CoA in the reaction led to the complete acylation of compound **3**, with the generation of derivatives with one and two propionyl groups. However, when isobutiryl‐CoA was used approximately half of compound **3** remained non‐acylated and only one derivative with one isobutiryl group was generated. Isobutiryl‐CoA differs from propionyl‐CoA by the presence of a methyl group at C2, which makes it bulkier and thus probably interfering in its interaction with the active site of the enzyme. These experiments demonstrate that CmmA has some tolerance towards its donor substrate. CmmA shows similarity to other acyltransferases involved in tailoring steps of antibiotics biosynthesis. Some of these acyltransferases (MdmB, AcyA and Asm19) have also shown considerable substrate tolerance for the acyl donor, but they were quite specific towards the acceptor substrate ([@b14]; [@b2]; [@b26]). On the contrary, CmmA is also able to acylate different substrates and at different positions, showing broader acceptor substrate flexibility. This highlights the potential of CmmA as a tool to create structural diversity and therefore to generate novel antitumour compounds.

![*In vitro* assays of CmmA using different acyl‐CoA donors. Analysis by HPLC of reaction products using membrane fraction, 4A,4E‐*O*‐dideacetyl‐chromomycin A~3~**3**, and (A) isobutyryl‐CoA or (B) propionyl‐CoA as acyl‐CoA donor substrates. 4A,4E‐*O*‐dideacetyl‐chromomycin A~3~ derivatives with one (★) or two (![](mbt0004-0226-fu2.jpg)) acyl groups.](mbt0004-0226-f6){#f6}

Experimental procedures
=======================

Strains, culture conditions, plasmids and DNA manipulation
----------------------------------------------------------

Several strains were used as biocatalysts for bioconversion experiments:*S. griseus* ssp. *griseus* ATCC 13273, chromomycin A~3~ producer, and the *S. griseus* mutant strains C60GI, C10GII, G10GIII and G10GIV, each one affected in a glycosyltransferase gene of the chromomycin biosynthesis gene cluster ([Fig. 2](#f2){ref-type="fig"}) ([@b21]). *Streptomyces albus* J1074 (*ilv‐1*, *sal‐2*; [@b16]) was used as host for expression of *cmmA*. Several *S. griseus* and *S. argillaceus* recombinant strains were used to prepare substrates for bioconversion experiments and enzyme assays (see [Fig. 1](#f1){ref-type="fig"}): *S. griseus* C10A to produce **3** ([@b20]); *S. argillaceus* ATCC12956 for **1**; *S. argillaceus* (pMP3\*BII) for **4** and **5**; *S. argillaceus* (pFL845) for **6**; *S. argillaceus* (pMP1\*BII) for **7**; *S. argillaceus* M7U1 (pFL845) for **8** ([@b3]; [@b29]); and *S. argillaceus* M7W1 for **9** and **10** ([@b32]; [@b1]). For sporulation on solid medium, the organisms were grown at 30°C on plates containing A medium ([@b12]), supplemented with 25 µg ml^−1^ thiostrepton when appropriate. For growth in liquid medium, the organisms were grown either in TSB medium (trypticase soya broth; Oxoid) or in R5A medium ([@b12]), supplemented with 5 µg ml^−1^ thiostrepton when appropriate. pEM4T was used for expressing genes in *Streptomyces* ([@b21]). *Escherichia coli* DH10B (Invitrogen) was used as a host for subcloning. Plasmid pQE60CmmA was used as source of *cmmA* (N. Menéndez, unpublished). DNA manipulations were performed according to standard techniques for *E. coli* ([@b34]) and *Streptomyces* ([@b16]).

PCR amplification and gene expression
-------------------------------------

For amplification of *cmmA*, pQE60cmmA was used as DNA template and the following oligoprimers: 5′‐GGACTAGTCCTAGGGGACGAAAGAGGCAGGATG‐3′ (SpeI and AvrII sites underlined) and 5′‐GCTCTAGATCAGTGGTGGTGGTGGTGGTG‐3′ (XbaI site underlined). PCR conditions were as follows: 100 ng of template DNA was mixed with 30 pmol of each primer and 1.25 units of *Pfx* DNA polymerase (Invitrogen) in a total reaction volume of 50 µl containing 2 µM each dNTP, 10 mM KCl, 10 mM (NH~4~)~2~SO~4~, 20 mM Tris‐HCl (pH 8.8), 2 mM MgSO~4~ and 0.1% Triton X‐100. The polymerization reaction was performed in a thermocycler (MiniCycler; MJ Research) under the following conditions: an initial denaturation of 2 min at 94°C; 30 cycles of 15 s at 94°C, 30 s at 55°C and 1 min at 68°C; after the 30 cycles, an extra extension step of 5 min at 68°C and another of 15 min at 4°C were added. After PCR amplification, the amplicon containing *cmmA* was digested with SpeI and XbaI, treated with Klenow polymerase and subcloned into the EcoRI site pre‐treated with Klenow polymerase of pEM4T. In the resultant plasmid (pEM4TcmmA), *cmmA* is under the control of the *ermE*\*p.

Bioconversion experiments
-------------------------

*Streptomyces griseus* wild type or the appropriate mutant strain was cultivated in TSB liquid medium with shaking at 30°C for 24 h. One hundred microlitres of the resultant cultures were used as pre‐inoculum to inoculate Erlenmeyer flasks containing 5 ml of R5A liquid medium. After 24 h of incubation, 15 µg per ml of the substrate (final concentration) was added, and further incubation was carried out for 24 h. In the case of mutants *S. griseus* C10GIII and *S. griseus* C10GIV, cultures were supplemented with 2 µg ml^−1^**2** (final concentration) in order to induce expression of chromomycin biosynthesis genes ([@b21]). After incubation, samples (1 ml) were extracted with 1 volume of ethyl acetate: formic acid (100:1). Organic extracts were dried under vacuum, and residues were eventually dissolved in a small volume of methanol before HPLC analysis.

HPLC analysis and purification of novel compounds
-------------------------------------------------

Chromatographic analyses were performed by HPLC‐MS as previously described ([@b28]), except that bidimensional chromatograms were extracted at 280 nm. Acetylated derivatives were obtained in bioconversion experiments in R5A medium supplemented with 15 µg ml^−1^ of the precursor molecule. Approximately 1.2 l of culture was prepared to obtain 4E‐*O*‐acetyl‐mithramycin **11**, whereas the derivatives of **5** were obtained from 5 l of culture. In both cases, the cultures were centrifuged and the supernatants were filtered and applied to a solid‐phase extraction cartridge (Sep‐Pak Vac C18, 10 g, Waters). The retained material was eluted with a mixture of methanol and 0.05% trifluoroacetic acid (TFA) in water. A linear gradient from 0 to 100% methanol in 60 min, at 10 ml min^−1^, was used. Fractions were taken every 5 min and analysed by UPLC. Fractions containing the desired compounds were neutralized with 3 ml of 0.1 M phosphate buffer (pH 7.0) and evaporated *in vacuo*. The resulting extracts were redissolved in a small volume of a mixture of DMSO and methanol (50:50) and the products were purified by preparative HPLC using a SunFire C18 column (10 × 250 mm, Waters). Compounds were chromatographed with mixtures of acetonitrile or methanol and 0.05% TFA in water, in isocratic conditions optimized for each peak, at 7 ml min^−1^. During all purification steps, the peaks were collected on 0.1 M phosphate buffer (pH 7.0). The solutions obtained were partially evaporated in rotavapour to reduce the concentration of the organic solvent and then applied to a solid‐phase extraction cartridge (Sep‐Pak Vac C18, Waters), washed with water to remove salts, eluted with methanol and finally lyophilized.

An alternative method was carried out for the purification of 4D‐*O*‐acetyl‐mithramycin SK **17**. In this case, 2 l of R5A medium for the bioconversion experiment was supplemented with 50 µg ml^−1^ of the precursor molecule. The culture was centrifuged and the supernatant was filtered and solid‐phase extracted (Sep‐Pak Vac C18, 10 g, Waters). A linear gradient of methanol and water (0--100% methanol during 60 min at 10 ml min^−1^) was applied for elution of the retained material. Fractions obtained were analysed by HPLC and those containing the acetylated derivative were pooled and dried *in vacuo*. The extract was redissolved in 5 ml of methanol and the purification procedure was carried out in a preparative column (XBridge^TM^ Prep C18, 5 µm, 30 × 150 mm, Waters) with isocratic elution using MeCN and 0.1% TFA in water (45:55), at 20 ml min^−1^. As TFA was used in the mobile phase of the purification, the peak was collected on 0.1 M potassium phosphate buffer (pH 7.0) and diluted fourfold with water to be desalted and concentrated by solid‐phase extraction, being finally lyophilized. The yields for the different compounds were as follows: 3.1 mg of **11**; 1.7 mg of **12**; 4.6 mg of **13**; 1.0 mg of **14**; 1.8 mg of **15**; 2.5 mg of **16**; and 5.2 mg of **17**.

Structure elucidation and characterization of new mithramycin derivatives
-------------------------------------------------------------------------

The structures of the new mithramycin analogues were elucidated by NMR spectroscopy, employing 1D ^1^H, ^13^C and homonuclear 2D ^1^H COSY/TOCSY experiments. All NMR data were recorded in acetone‐*d*~6~ at 298 K using a Bruker Avance Ultrashield Plus 600 spectrometer (600 MHz for ^1^H, 150 MHz for ^13^C experiments). Typical parameters for 2D experiments were: COSY/TOCSY, 256 and 2048 points in F1 and F2, respectively, 48 transients each. NMR experiments were processed using the program Topspin 1.3 (Bruker GmbH, Karlsruhe, Germany).

Determination of antitumour activity
------------------------------------

The antitumour activity of the mithramycin derivatives was tested against four tumour cell lines. Quantitative measurement of cell growth and viability was carried out using the MTT tetrazolium assay ([@b25]). Values correspond to the average of three independent assays.

Cell fractionation
------------------

To determine the location of the CmmA protein, *S. albus* pEM4TcmmA was grown in TSB medium at 30°C with orbital shaking for 48 h. Cultures were centrifuged and the mycelium was washed twice with 50 mM Tris‐HCl (pH 7.5), 1 mM EDTA and 20% glycerol. The mycelium was disrupted by two passes through a French press at a pressure of 10.3 MPa. DNA was broken by ultrasound (six pulses of 15 s each with intermittent cooling on ice water) in a MSE ultrasonic disintegrator at 150 watts and 50 kHz. Unbroken cells and debris were removed by centrifugation at 12 000 *g* for 30 min. Samples were collected from the resultant supernatant and were named 'cell‐free extracts'. The supernatant was further centrifuged at 69 000 *g* for 1 h. The resulting supernatant was designated 'soluble fraction'. The pellet containing the cell membranes was resuspended in a small volume of the above‐mentioned buffer and was named 'membrane fraction'. Protein estimation in the different samples was carried out by measurement of absorbance at 540 nm by a protein‐dye binding assay using bovine serum albumin as standard ([@b6]).

Polyacrylamide gel electrophoresis and Western analysis
-------------------------------------------------------

Protein analysis was carried out by polyacrylamide gel electrophoresis in the presence of SDS ([@b17]). Western blotting was performed as described ([@b7]), using the developing kit ECL plus Western Blotting Detection System (Amersham Biosciences). A peptide (ARPGDSTRSFYRRC) corresponding to the second predicted cytoplasmic loop of CmmA was synthesized to produce anti‐CmmA serum (SigmaGenosys).

*In vitro* assays of CmmA
-------------------------

Acetylation assays were conducted in a total volume of 50 µl in Tris‐HCl 50 mM pH 8, EDTA 1 mM and glycerol 20%, including 100 µM **3**, 130 µg of protein from the membrane fraction (or the corresponding cell fraction to be tested) and 500 µM acetyl‐CoA. After incubation at 30°C for 2 h, the reaction products were extracted twice with 50 µl of ethyl acetate acidified with 3 µl of 0.4 N HCl. After phase separation, the organic phase was recovered, the solvent evaporated and the residue were suspended in 50 µl of methanol prior analysed by HPLC. Assays were also carried out using other acyl‐CoA donors (2 mM final concentration): isovaleryl‐CoA, isobutyryl‐CoA, β‐methylcrotonyl‐CoA, propionyl‐CoA and succinyl‐CoA.

This work was supported by grants (to C.M.) from the Spanish Ministry of Education and Science (BIO2005‐04115 and PET2005‐0401) and from the Spanish Ministry of Science and Innovation (BIO2008‐00269). B.G. was the recipient of a predoctoral fellowship from the Spanish Ministry of Science and Innovation. Instituto Biomar S.A. is acknowledged for helping us with the antitumour assays.
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**Fig. S1.**^1^H‐NMR full chart for 4E‐*O*‐acetyl‐mithramycin (**11**) in acetone‐*d*6. (600 MHz)

**Fig. S2.**^1^H‐NMR expanded chart for 4E‐*O*‐acetyl‐mithramycin (**11**) in acetone‐*d*6. (600 MHz)

**Fig. S3.**^13^C‐NMR chart for 4E‐*O*‐acetyl‐mithramycin (**11**) in acetone‐*d*6. (150 MHz)

**Fig. S4.** COSY chart for 4E‐*O*‐acetyl‐mithramycin (**11**) in acetone‐*d*6 (256 points for F1 and F2, 48 transients)

**Fig. S5.** TOCSY chart for 4E‐*O*‐acetyl‐mithramycin (**11**) in acetone‐*d*6 (2048 points for F1 and F2, 48 transients)

**Fig. S6.**^1^H‐NMR full chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐3E‐*O*‐acetyl‐mithramycin (**12**) in acetone‐*d*6. (600 MHz)

**Fig. S7.**^1^H‐NMR expanded chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐3E‐*O*‐acetyl‐mithramycin (**12**) in acetone‐*d*6. (600 MHz)

**Fig. S8.** COSY chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐3E‐*O*‐acetyl‐mithramycin (**12**) in acetone‐*d*6 (256 points for F1 and F2, 48 transients)

**Fig. S9.** TOCSY chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐3E‐*O*‐acetyl‐mithramycin (**12**) in acetone‐*d*6 (2048 points for F1 and F2, 48 transients)

**Fig. S10.**^1^H‐NMR full chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐4D‐*O*‐acetyl‐mithramycin (**13**) in acetone‐*d*6. (600 MHz)

**Fig. S11.**^1^H‐NMR expanded chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐4D‐*O*‐acetyl‐mithramycin (**13**) in acetone‐*d*6. (600 MHz)

**Fig. S12.** COSY chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐4D‐*O*‐acetyl‐mithramycin (**13**) in acetone‐*d*6 (256 points for F1 and F2, 48 transients)

**Fig. S13.** TOCSY chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐4D‐*O*‐acetyl‐mithramycin (**13**) in acetone‐*d*6 (2048 points for F1 and F2, 48 transients)

**Fig. S14.**^1^H‐NMR full chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐4E‐*O*‐acetyl‐mithramycin (**14**) in acetone‐*d*6. (600 MHz)

**Fig. S15.**^1^H‐NMR expanded chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐4E‐*O*‐acetyl‐mithramycin (**14**) in acetone‐*d*6. (600 MHz)

**Fig. S16.** COSY chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐4E‐*O*‐acetyl‐mithramycin (**14**) in acetone‐*d*6 (256 points for F1 and F2, 48 transients)

**Fig. S17.** TOCSY chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐4E‐*O*‐acetyl‐mithramycin (**14**) in acetone‐*d*6 (2048 points for F1 and F2, 48 transients)

**Fig. S18.**^1^H‐NMR full chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐3E, 4D‐*O*‐diacetyl‐mithramycin (**15**) in acetone‐*d*6. (600 MHz)

**Fig. S19.**^1^H‐NMR expanded chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐3E, 4D‐*O*‐diacetyl‐mithramycin (**15**) in acetone‐*d*6. (600 MHz)

**Fig. S20.** COSY chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐3E, 4D‐*O*‐diacetyl‐mithramycin (**15**) in acetone‐*d*6 (256 points for F1 and F2, 48 transients)

**Fig. S21.** TOCSY chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐3E, 4D‐*O*‐diacetyl‐mithramycin (**15**) in acetone‐*d*6 (2048 points for F1 and F2, 48 transients)

**Fig. S22.**^1^H‐NMR full chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐3E, 4E, 4D‐*O*‐triacetyl‐mithramycin (**16**) in acetone‐*d*6. (600 MHz)

**Fig. S23.**^1^H‐NMR expanded chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐3E, 4E, 4D‐*O*‐triacetyl‐mithramycin (**16**) in acetone‐*d*6. (600 MHz)

**Fig. S24.** COSY chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐3E, 4E, 4D‐*O*‐triacetyl‐mithramycin (**16**) in acetone‐*d*6 (256 points for F1 and F2, 48 transients)

**Fig. S25.** TOCSY chart for demycarosyl‐3D‐b‐D‐digitoxosyl‐3E, 4E, 4D‐*O*‐triacetyl‐mithramycin (**16**) in acetone‐*d*6 (2048 points for F1 and F2, 48 transients)

**Fig. S26.**^1^H‐NMR full chart for 4D‐*O*‐acetyl‐mithramycin SK (**17**) in acetone‐*d*6. (600 MHz)

**Fig. S27.**^1^H‐NMR expanded chart for 4D‐*O*‐acetyl‐mithramycin SK (**17**) in acetone‐*d*6. (600 MHz)

**Fig. S28.**^13^C‐NMR chart for 4D‐*O*‐acetyl‐mithramycin SK (**17**) in acetone‐*d*6. (150 MHz)

**Fig. S29.** COSY chart for 4D‐*O*‐acetyl‐mithramycin SK (**17**) in acetone‐*d*6 (256 points for F1 and F2, 48 transients)

**Fig. S30.** TOCSY chart for 4D‐*O*‐acetyl‐mithramycin SK (**17**) in acetone‐*d*6 (2048 points for F1 and F2, 48 transients)

**Table S1.** NMR data for 4E‐*O*‐acetyl‐mithramycin (**11**) in acetone‐*d*6. (^1^H, 600 MHz; ^13^C, 150 MHz).

**Table S2.** NMR data for demycarosyl‐3D‐β‐d‐digitoxosyl‐3E‐*O*‐acetyl‐mithramycin (**12**) in acetone‐*d*6. (^1^H, 600 MHz).

**Table S3.** NMR data for demycarosyl‐3D‐β‐d‐digitoxosyl‐4D‐*O*‐acetyl‐mithramycin (**13**) in acetone‐*d*6. (^1^H, 600 MHz).

**Table S4.** NMR data for demycarosyl‐3D‐β‐d‐digitoxosyl‐4E‐*O*‐acetyl‐mithramycin (**14**) in acetone‐*d*6. (^1^H, 600 MHz).

**Table S5.** NMR data for demycarosyl‐3D‐β‐d‐digitoxosyl‐3E,4D‐*O*‐diacetyl‐mithramycin (**15**) in acetone‐*d*6. (^1^H, 600 MHz).

**Table S6.** NMR data for demycarosyl‐3D‐β‐d‐digitoxosyl‐3E,4E,4D‐*O*‐triacetyl‐mithramycin (**16**) in acetone‐*d*6. (^1^H, 600 MHz).

**Table S7.** NMR data for 4D‐*O*‐acetyl‐mithramycin SK (**17**) in acetone‐*d*6. (^1^H, 600 MHz; ^13^C, 150 MHz).
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